Dermatologic Manifestations of Pityriasis Alba Clinical Presentation

  • Author: Bassam Zeina, MD, PhD; Chief Editor: Dirk M Elston, MD   more...
 
Updated: Dec 9, 2011
 

History

Lesions in pityriasis alba are commonly asymptomatic, although some patients report mild pruritus or a burning sensation.

Lesions tend to worsen in the summer with increased sun exposure.

Erythema is usually mild and may initially be conspicuous. Minimal serous crusting may even occur at a few points on the surface of some of the pityriasis alba plaques. Erythema later subsides completely to leave areas of hypopigmentation with or without fine scaling.

At the stage when a physician commonly observes pityriasis alba lesions, they show only persistent fine scaling and depigmentation. This commonly induces the patient to seek advice.

Pityriasis alba may be conspicuous in heavily pigmented skin. In lighter skins, pityriasis alba may become conspicuous after sun tanning. Pityriasis alba is considered a skin disorder of late summer because reports describe that excessive and unprotected sun exposure are strongly related in the development of pityriasis alba.[6]

Pityriasis alba is associated with atopic diathesis. Inquire about a patient and family history of eczema, asthma, and/or hayfever.[7]

The course of pityriasis alba is extremely variable. Most cases persist for several months, and some still show hypopigmentation for a year or more after all scaling subsides. Hypopigmentation may persist for years but eventually resolves spontaneously.

Recurrent crops of new lesions may develop at intervals.

The average duration of the common facial form in childhood is a year or more.

Widespread cases overlap with a condition termed progressive and extensive hypomelanosis.[8] Progressive and extensive hypomelanosis occurs mainly in women from 18-25 years, with progressive development of round, pale coalescent macules mainly on the back that are unresponsive to therapy but spontaneously regress within 3-4 years.[9]

Next

Physical

The individual pityriasis alba lesion is a rounded, oval, or irregular plaque that is red, pink, or skin colored and has fine lamellar or branny scaling with indistinct margins. Several patches are usually observed.

In children, pityriasis alba lesions are often confined to the face and are most common around the mouth, chin, and cheeks (see the image below). Legs and trunk are less commonly involved.

Pityriasis alba. Pityriasis alba.

In 20% of affected children, the neck, arms, and face are involved. Less commonly, the face is spared and scattered pityriasis alba lesions are observed on the trunk and limbs.

Pityriasis alba lesions usually range from 0.5-2 cm in diameter but may be larger, especially on the trunk.

Two uncommon variants exist, a pigmenting variety and an extensive type. In pigmenting pityriasis alba, the typical lesion is a central zone of bluish hyperpigmentation surrounded by a hypopigmented, slightly scaly halo of variable width, usually confined to the face and often associated with dermatophyte infection.[10] Extensive pityriasis alba is differentiated from the classic form by the widespread and symmetrical involvement of the skin, no preceding inflammatory phase, a higher female-to-male ratio, and, histologically, the absence of spongiosis.[11] In the extensive variant, lesions are less erythematous and less scaly, more persistent, asymptomatic, and more frequently seen on the trunk and less on the face.[1]

Previous
Next

Causes

The cause is unknown. The condition has been regarded as a manifestation of atopic dermatitis or other mild forms of eczema.

Reported contributory factors related to the development of pityriasis alba are excessive and unprotected sun exposure, poor hygienic habits, and environmental influences such as temperature, humidity, and altitude.[6]

Previous
 
 
Contributor Information and Disclosures
Author

Bassam Zeina, MD, PhD  Consulting Staff, Department of Dermatology, Milton Keynes Hospital, UK

Bassam Zeina, MD, PhD is a member of the following medical societies: British Association of Dermatologists, British Medical Association, and Royal Society of Medicine

Disclosure: Nothing to disclose.

Coauthor(s)

Nicole Sakka, MBBS  Foundation Year 2, Royal Liverpool and Broadgreen University Hospital, Liverpool, UK

Disclosure: Nothing to disclose.

Sohail Mansoor, MBBS, MSc  Dermatologist and Lead Physician in Dermatologic Surgery, Department of Dermatology, Barnet Hospital, UK

Sohail Mansoor, MBBS, MSc is a member of the following medical societies: American Academy of Anti-Aging Medicine, American Academy of Dermatology, American Society for Dermatologic Surgery, Royal College of Physicians and Surgeons of Glasgow, and Royal College of Physicians of the United Kingdom

Disclosure: Nothing to disclose.

Specialty Editor Board

Mark G Lebwohl, MD  Chairman, Department of Dermatology, Mount Sinai School of Medicine

Mark G Lebwohl, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Amgen/Pfizer Honoraria Consulting; Centocor/Janssen Honoraria Consulting; DermiPsor Honoraria Consulting; GlaxoSmithKline Honoraria Consulting; HelixBioMedix Honoraria Consulting; Novartis Honoraria Consulting; Ranbaxy Lectures; Can-Fite Biopharma Honoraria Consulting; DermaGenoma Honoraria Consulting; Biosynexus Honoraria Consulting

David F Butler, MD  Professor of Dermatology, Texas A&M University College of Medicine; Chair, Department of Dermatology, Director, Dermatology Residency Training Program, Scott and White Clinic, Northside Clinic

David F Butler, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Medical Association, American Society for Dermatologic Surgery, American Society for MOHS Surgery, Association of Military Dermatologists, and Phi Beta Kappa

Disclosure: Nothing to disclose.

Christen M Mowad, MD  Associate Professor, Department of Dermatology, Geisinger Medical Center

Christen M Mowad, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, and Phi Beta Kappa

Disclosure: Nothing to disclose.

Catherine M Quirk, MD  Clinical Assistant Professor, Department of Dermatology, University of Pennsylvania

Catherine M Quirk, MD is a member of the following medical societies: Alpha Omega Alpha and American Academy of Dermatology

Disclosure: Nothing to disclose.

Chief Editor

Dirk M Elston, MD  Director, Ackerman Academy of Dermatopathology, New York

Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

Additional Contributors

The authors and editors of Medscape Reference gratefully acknowledge the contributions of previous author, Mohsin Ali, MBBS, FRCP, MRCP, to the development and writing of this article.

References
  1. Sandhu K, Handa S, Kanwar AJ. Extensive pityriasis alba in a child with atopic dermatitis. Pediatr Dermatol. May-Jun 2004;21(3):275-6. [Medline].

  2. Watkins DB. Pityriasis alba: a form of atopic dermatitis. A preliminary report. Arch Dermatol. Jun 1961;83:915-9. [Medline].

  3. Gambichler T, Kramer HJ, Boms S, et al. Quantification of ultraviolet protective effects of pityriacitrin in humans. Arch Dermatol Res. Dec 2007;299(10):517-20. [Medline].

  4. Walker SL, Shah M, Hubbard VG, Pradhan HM, Ghimire M. Skin disease is common in rural Nepal: results of a point prevalence study. Br J Dermatol. Feb 2008;158(2):334-8. [Medline].

  5. Martin RF, Lugo-Somolinos A, Sanchez JL. Clinicopathologic study on pityriasis alba. Bol Asoc Med P R. Oct 1990;82(10):463-5. [Medline].

  6. Blessmann Weber M, Sponchiado de Avila LG, Albaneze R, Magalhaes de Oliveira OL, Sudhaus BD, Cestari TF. Pityriasis alba: a study of pathogenic factors. J Eur Acad Dermatol Venereol. Sep 2002;16(5):463-8. [Medline].

  7. Rigopoulos D, Gregoriou S, Charissi C, Kontochristopoulos G, Kalogeromitros D, Georgala S. Tacrolimus ointment 0.1% in pityriasis alba: an open-label, randomized, placebo-controlled study. Br J Dermatol. Jul 2006;155(1):152-5. [Medline].

  8. Di Lernia V, Ricci C. Progressive and extensive hypomelanosis and extensive pityriasis alba: same disease, different names?. J Eur Acad Dermatol Venereol. May 2005;19(3):370-2. [Medline].

  9. Guillet G, Helenon R, Gauthier Y, Surleve-Bazeille JE, Plantin P, Sassolas B. Progressive macular hypomelanosis of the trunk: primary acquired hypopigmentation. J Cutan Pathol. Oct 1988;15(5):286-9. [Medline].

  10. du Toit MJ, Jordaan HF. Pigmenting pityriasis alba. Pediatr Dermatol. Mar 1993;10(1):1-5. [Medline].

  11. Di Lernia V, Ricci C. Progressive and extensive hypomelanosis and extensive pityriasis alba: same disease, different names?. J Eur Acad Dermatol Venereol. May 2005;19(3):370-2. [Medline].

  12. Whitmore SE, Simmons-O'Brien E, Rotter FS. Hypopigmented mycosis fungoides. Arch Dermatol. Apr 1994;130(4):476-80. [Medline].

  13. In SI, Yi SW, Kang HY, Lee ES, Sohn S, Kim YC. Clinical and histopathological characteristics of pityriasis alba. Clin Exp Dermatol. Jul 2009;34(5):591-7. [Medline].

  14. Vargas-Ocampo F. Pityriasis alba: a histologic study. Int J Dermatol. Dec 1993;32(12):870-3. [Medline].

  15. Zaynoun ST, Aftimos BG, Tenekjian KK, Bahuth N, Kurban AK. Extensive pityriasis alba: a histological histochemical and ultrastructural study. Br J Dermatol. Jan 1983;108(1):83-90. [Medline].

  16. Harper J. Topical corticosteroids for skin disorders in infants and children. Drugs. 1988;36 Suppl 5:34-7. [Medline].

  17. Fujita WH, McCormick CL, Parneix-Spake A. An exploratory study to evaluate the efficacy of pimecrolimus cream 1% for the treatment of pityriasis alba. Int J Dermatol. Jul 2007;46(7):700-5. [Medline].

  18. O'Farreli N. Pityriasis alba. Arch Dermatol. 1956;73:376-7.

Previous
Next
 
Pityriasis alba.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.